Compare Agilysys Inc (AGYS) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs BridgeBio Pharma Inc — how do they compare? Agilysys Inc trades at $106.06 (market cap $3.02B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B). The key difference: BridgeBio Pharma Inc is far larger — about 5.5× Agilysys Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Agilysys Inc nearer its low. Which is the better fit depends on your goals.
| AGYS | BBIO | |
|---|---|---|
Market Cap | $3.02B | $16.61B |
Sector | Technology | Health |
52-Week High | $141.12 | $90.17 |
52-Week Low | $62.19 | $47.29 |
Enterprise Value | $2.92B | $18.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilysys (AGYS) trades at $108.58, up 0.93% with strong bullish momentum supported by recent earnings beats and positive analyst sentiment. The stock shows robust fundamental performance with Q1 2026 EPS of $0.63 beating expectations and record subscription revenue growth. Technical indicators suggest bullish momentum with the current price near pivot point resistance at $108, while moving averages signal continued upward trend potential.
The outlook remains positive with 100% analyst buy ratings and a $118.33 consensus price target representing 9% upside. Key catalysts include continued subscription growth and Marriott deployment progress, though elevated valuation multiples (P/E 70.45) and competitive pressures in hospitality software present risks requiring monitoring of execution consistency.
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
